Differential regulation of estrogen receptors α and β by 4-(E)-{(4-hydroxyphenylimino)-methylbenzene,1,2-diol}, a novel resveratrol analog

Journal of Steroid Biochemistry and Molecular Biology

Volumn 144, Issue PB, 2014, Pages 500-512

  Ronghe, Amruta ^a   Chatterjee, Anwesha ^a   Singh, Bhupendra ^b   Dandawate, Prasad ^c   Murphy, Leigh ^d   Bhat, Nimee K ^a   Padhye, Subhash ^c   Bhat, Hari K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Pune   (India)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Breast cancer; Estrogen receptors; Resveratrol; Resveratrol analogs

Indexed keywords

4 [(4 HYDROXYPHENYLIMINO)METHYLBENZENE,1,2 DIOL]; ANTINEOPLASTIC AGENT; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LACTATE DEHYDROGENASE; MESSENGER RNA; PROTEIN P21; PROTEIN P53; RESVERATROL; UNCLASSIFIED DRUG; 4 AMINOBENZOIC ACID DERIVATIVE; 4-((4-HYDROXYPHENYLIMINO)METHYLBENZENE-1,2-DIOL; CCND1 PROTEIN, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; SCHIFF BASE; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MCF 7 CELL LINE; MOLECULAR DOCKING; ONCOGENE C MYC; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; MOLECULAR DOCKING SIMULATION; PARA-AMINOBENZOATES; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SCHIFF BASES; STILBENES;

EID: 84908115748     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.09.015     Document Type: Article

References (59)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J. Clin. 63 2013 11 30
2. M.M. Shinohara, G. Tozbikian, J.T. Wolfe, S.J. Shin, C. Mies, and R. Elenitsas Cutaneous metastatic breast carcinoma with clear cell features J. Cutan. Pathol. 40 2013 753 757
3. C. DeSantis, J. Ma, L. Bryan, and A. Jemal Breast cancer statistics, 2013 CA Cancer J. Clin. 64 2014 52 62
4. H.K. Bhat, G. Calaf, T.K. Hei, T. Loya, and J.V. Vadgama Critical role of oxidative stress in estrogen-induced carcinogenesis Proc. Natl. Acad. Sci. U. S. A. 100 2003 3913 3918
5. B. Singh, and H.K. Bhat Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage and is associated with inhibition of estrogen-induced breast cancer Carcinogenesis 33 2012 2601 2610
6. S.M. Mense, F. Remotti, A. Bhan, B. Singh, M. El-Tamer, T.K. Hei, and H.K. Bhat Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure Toxicol. Appl. Pharmacol. 232 2008 78 85
7. J.D. Yager, and J.G. Liehr Molecular mechanisms of estrogen carcinogenesis Annu. Rev. Pharmacol. Toxicol. 36 1996 203 232
8. R. Nelson Steroidal oestrogens added to list of known human carcinogens Lancet 360 2002 2053
9. M. Le Romancer, C. Poulard, P. Cohen, S. Sentis, J.M. Renoir, and L. Corbo Cracking the estrogen receptor's posttranslational code in breast tumors Endocr. Rev. 32 2011 597 622
10. B. Singh, N.K. Bhat, and H.K. Bhat Partial inhibition of estrogen-induced mammary carcinogenesis in rats by tamoxifen: balance between oxidant stress and estrogen responsiveness PLoS One 6 2011 e25125
11. E.L. Cavalieri, and E.G. Rogan A unifying mechanism in the initiation of cancer and other diseases by catechol quinones Ann. NY. Acad. Sci. 1028 2004 247 257
12. M.M. Patel, and H.K. Bhat Differential oxidant potential of carcinogenic and weakly carcinogenic estrogens: involvement of metabolic activation and cytochrome P450 J. Biochem. Mol. Toxicol. 18 2004 37 42
13. B. Singh, N.K. Bhat, and H.K. Bhat Induction of NAD(P)H-quinone oxidoreductase 1 by antioxidants in female ACI rats is associated with decrease in oxidative DNA damage and inhibition of estrogen-induced breast cancer Carcinogenesis 33 2012 156 163
14. B. Singh, S.M. Mense, F. Remotti, X. Liu, and H.K. Bhat Antioxidant butylated hydroxyanisole inhibits estrogen-induced breast carcinogenesis in female ACI rats J. Biochem. Mol. Toxicol. 23 2009 202 211
15. N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, and J.A. Gustafsson Estrogen receptors: how do they signal and what are their targets Physiol. Rev. 87 2007 905 931
16. J.M. Hall, J.F. Couse, and K.S. Korach The multifaceted mechanisms of estradiol and estrogen receptor signaling J. Biol. Chem. 276 2001 36869 36872
17. V. Bartella, P. Rizza, I. Barone, D. Zito, F. Giordano, C. Giordano, S. Catalano, L. Mauro, D. Sisci, M.L. Panno, S.A. Fuqua, and S. Ando Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter Breast Cancer Res. Treat. 134 2012 569 581
18. J. Matthews, and J.A. Gustafsson Estrogen signaling: a subtle balance between ER alpha and ER beta Mol. Interv. 3 2003 281 292
19. E.M.R.J. Fox, Davis, and M.A. Shupnik ERbeta in breast cancer-onlooker, passive player, or active protector? Steroids 73 2008 1039 1051
20. P. Roger, M.E. Sahla, S. Makela, J.A. Gustafsson, P. Baldet, and H. Rochefort Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors Cancer Res. 61 2001 2537 2541
21. E. Leygue, H. Dotzlaw, P.H. Watson, and L.C. Murphy Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis Cancer Res. 58 1998 3197 3201
22. T. Kuukasjarvi, J. Kononen, H. Helin, K. Holli, and J. Isola Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J. Clin. Oncol. 14 1996 2584 2589
23. C. Palmieri, G.J. Cheng, S. Saji, M. Zelada-Hedman, A. Warri, Z. Weihua, S. Van Noorden, T. Wahlstrom, R.C. Coombes, M. Warner, and J.A. Gustafsson Estrogen receptor beta in breast cancer Endocr. Relat. Cancer. 9 2002 1 13
24. L.C. Murphy, and E. Leygue The role of estrogen receptor-β in breast cancer Semin. Reprod. Med. 30 2012 5 13
25. J. Hartman, K. Lindberg, A. Morani, J. Inzunza, A. Strom, and J.A. Gustafsson Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts Cancer Res. 66 2006 11207 11213
26. C. Williams, K. Edvardsson, S.A. Lewandowski, A. Strom, and J.A. Gustafsson A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells Oncogene 27 2008 1019 1032
27. A.M. Shaaban, P.A. O'Neill, M.P. Davies, R. Sibson, C.R. West, P.H. Smith, and C.S. Foster Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia Am. J. Surg. Pathol. 27 2003 1502 1512
28. H. Adlercreutz Phytoestrogens: epidemiology and a possible role in cancer protection Environ. Health Perspect. 103 1995 103 112 Suppl 7
29. S.M. Mense, T.K. Hei, R.K. Ganju, and H.K. Bhat Phytoestrogens and breast cancer prevention: possible mechanisms of action Environ. Health Perspect. 116 2008 426 433
30. H. Adlercreutz Phytoestrogens and breast cancer J. Steroid Biochem. Mol. Biol. 83 2002 113 118
31. J. An, C. Tzagarakis-Foster, T.C. Scharschmidt, N. Lomri, and D.C. Leitman Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens J. Biol. Chem. 276 2001 17808 17814
32. G.G. Kuiper, J.G. Lemmen, B. Carlsson, J.C. Corton, S.H. Safe, P.T. van der Saag, B. van der Burg, and J.A. Gustafsson Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta Endocrinology 139 1998 4252 4263
33. M. Athar, J.H. Back, L. Kopelovich, D.R. Bickers, and A.L. Kim Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms Arch. Biochem. Biophys. 486 2009 95 102
34. S. Garvin, K. Ollinger, and C. Dabrosin Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo Cancer Lett. 231 2006 113 122
35. E.L. Cavalieri, and E.G. Rogan Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer J. Steroid Biochem. Mol. Biol. 125 2011 169 180
36. B. Singh, R. Shoulson, A. Chatterjee, A. Ronghe, N.K. Bhat, D.C. Dim, and H.K. Bhat Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways Carcinogenesis 35 2014 1872 1880
37. K.P. Bhat, D. Lantvit, K. Christov, R.G. Mehta, R.C. Moon, and J.M. Pezzuto Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models Cancer Res. 61 2001 7456 7463
38. J.L. Bowers, V.V. Tyulmenkov, S.C. Jernigan, and C.M. Klinge Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta Endocrinology 141 2000 3657 3667
39. T. Walle Bioavailability of resveratrol Ann. NY Acad. Sci. 1215 2011 9 15
40. A. Siddiqui, P. Dandawate, R. Rub, S. Padhye, S. Aphale, A. Moghe, A. Jagyasi, K. Venkateswara Swamy, B. Singh, A. Chatterjee, A. Ronghe, and H.K. Bhat Novel Aza-resveratrol analogs: synthesis, characterization and anticancer activity against breast cancer cell lines Bioorg. Med. Chem. Lett. 23 2013 635 640
41. H.K. Bhat, and I. Epelboym Quantitative analysis of total mitochondrial DNA: competitive polymerase chain reaction versus real-time polymerase chain reaction J. Biochem. Mol. Toxicol. 18 2004 180 186
42. H.K. Bhat, H.J. Hacker, P. Bannasch, E.A. Thompson, and J.G. Liehr Localization of estrogen receptors in interstitial cells of hamster kidney and in estradiol-induced renal tumors as evidence of the mesenchymal origin of this neoplasm Cancer Res. 53 1993 5447 5451
43. S.M. Mense, J. Chhabra, and H.K. Bhat Preferential induction of cytochrome P450 1A1 over cytochrome P450 1B1 in human breast epithelial cells following exposure to quercetin J. Steroid Biochem. Mol. Biol. 110 2008 157 162
44. B. Singh, A. Chatterjee, A.M. Ronghe, N.K. Bhat, and H.K. Bhat Antioxidant-mediated up-regulation of OGG1 via NRF2 induction is associated with inhibition of oxidative DNA damage in estrogen-induced breast cancer BMC Cancer 13 2013 253
45. B. Singh, A.M. Ronghe, A. Chatterjee, N.K. Bhat, and H.K. Bhat MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis Carcinogenesis 34 2013 1165 1172
46. O. Trott, and A.J. Olson AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 31 2010 455 461
47. Z. Wang, Y. Li, C. Ai, and Y. Wang In silico prediction of estrogen receptor subtype binding affinity and selectivity using statistical methods and molecular docking with 2-arylnaphthalenes and 2-arylquinolines Int. J. Mol. Sci. 11 2010 3434 3458
48. D. Seeliger, and B.L. de Groot Ligand docking and binding site analysis with PyMOL and Autodock/Vina J. Comput. Aided Mol. Des. 24 2010 417 422
49. H.K. Bhat, and J.V. Vadgama Role of estrogen receptor in the regulation of estrogen induced amino acid transport of System A in breast cancer and other receptor positive tumor cells Int. J. Mol. Med. 9 2002 271 279
50. S. Zhang, H.J. Cao, F.B. Davis, H.Y. Tang, P.J. Davis, and H.Y. Lin Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells Br. J. Cancer 91 2004 178 185
51. A. Polotskaia, S. Hoffman, N.L. Krett, M. Shanmugam, and S.T. Rosen 8-Amino-adenosine activates p53-independent cell death of metastatic breast cancers Mol. Cancer Ther. 11 2012 2495 2504
52. C. Wang, J.A. Mayer, A. Mazumdar, K. Fertuck, H. Kim, M. Brown, and P.H. Brown Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor Mol. Endocrinol. 25 2011 1527 1538
53. M. Dadiani, D. Seger, T. Kreizman, D. Badikhi, R. Margalit, R. Eilam, and H. Degani Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc Endocr. Relat. Cancer 16 2009 819 834
54. C.K. Osborne Tamoxifen in the treatment of breast cancer N. Engl. J. Med. 339 1998 1609 1618
55. E.K. Shanle, and W. Xu Selectively targeting estrogen receptors for cancer treatment Adv. Drug Deliv. Rev. 62 2010 1265 1276
56. S. Fulda Resveratrol and derivatives for the prevention and treatment of cancer Drug Discov. Today 15 2010 757 765
57. E.A. Musgrove, C.S. Lee, M.F. Buckley, and R.L. Sutherland Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle Proc. Natl. Acad. Sci. U. S. A. 91 1994 8022 8026
58. D. Weinstat-Saslow, M.J. Merino, R.E. Manrow, J.A. Lawrence, R.F. Bluth, K.D. Wittenbel, J.F. Simpson, D.L. Page, and P.S. Steeg Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions Nat. Med. 1 1995 1257 1260
59. S. Haupt, M. Berger, Z. Goldberg, and Y. Haupt Apoptosis - the p53 network J. Cell Sci. 116 2003 4077 4085